Prof Soria talks to ecancertv about the upcoming 15th International Congress on Targeted Anticancer Therapies (TAT 2017).

The role of Phase I studies in oncology drug development is changing, he says, explaining that Phase I is no longer just about checking for toxicity, but also enriching patients with better predictive markers of efficacy and ascertaining objective responses.

He tells us how TAT brings a blend of academics and industry partners together from all over the world, specialising in targeted therapies and immunotherapies.

Because of its size and because there are no parallel sessions, the programme is easy to follow and allows for friendly interactions between key opinion leaders, young investigators and industry, he says.

For more on the TAT congress, we also have an interview with Dr Lesley Seymour.